Growth HormoneEmerging

Ipamorelin

The first selective growth hormone secretagogue with no cortisol stimulation—a critical safety advantage over other GHRPs.

Also known as: GHRP-1 Derivative, Selective GHS

Subcutaneous

Available on Forge Amino

Ipamorelin 10MG — independently lab tested, 99%+ purity, QR-linked COA.

Source this compound →

Important: This content is for informational and research purposes only and is not intended for human or veterinary use. Consult your physician for health-related guidance and laboratory monitoring.

How It Works

Pentapeptide that selectively binds ghrelin receptor (GHSR-1a) on somatotroph cells, triggering GH pulse amplitude without off-target ACTH or cortisol release.

Key Benefits

  • Pulsatile GH release (physiologic pattern)
  • No cortisol or prolactin elevation
  • Enhanced muscle protein synthesis
  • Improved bone density
  • Enhanced GH secretion when stacked with CJC

Dosing Protocols

Beginner / Intermediate

Dose

100-200 mcg

Frequency

Before bed subcutaneous

Cycle Length

8-12 weeks

Notes

Inject on empty stomach; 2-3 injections daily optimal

Advanced

Dose

200-300 mcg

Frequency

2-3 times daily subcutaneous

Cycle Length

12-16 weeks

Notes

Bedtime injection most important; peak 40 min post-injection

Side Effects & Safety

Common Side Effects

  • Appetite stimulation
  • Mild nausea or dizziness
  • Injection site reactions (minimal)
  • Very safe; no serious AEs in trials

Contraindications

  • Pregnancy and breastfeeding
  • Active cancer or cancer history
  • Acute critical illness
  • Growth hormone-secreting tumors

Stacking & Synergies

These compounds have complementary mechanisms and may enhance results when used together.

CJC-1295CJC-1295 without DACResistance trainingProtein-rich diet

Key Takeaway

Selective GH amplification: Ipamorelin triggers GH pulses without cortisol—the safest GHRP available.

Research Disclaimer: This content is for informational and research purposes only. It is not medical advice. These products are not approved by the FDA for human consumption. Consult a qualified healthcare provider before starting any new protocol. The information provided is based on preclinical research and anecdotal reports and has not been formally evaluated in randomized controlled trials.